Cassava Sciences Inc (SAVA)
32.18
+6.13
(+23.53%)
USD |
NASDAQ |
Nov 21, 16:00
33.00
+0.82
(+2.55%)
After-Hours: 20:00
Cassava Sciences Enterprise Value: 1.399B for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 1.399B |
| November 20, 2024 | 1.104B |
| November 19, 2024 | 1.198B |
| November 18, 2024 | 1.196B |
| November 15, 2024 | 1.146B |
| November 14, 2024 | 1.109B |
| November 13, 2024 | 1.062B |
| November 12, 2024 | 1.120B |
| November 11, 2024 | 1.153B |
| November 08, 2024 | 1.148B |
| November 07, 2024 | 1.070B |
| November 06, 2024 | 1.129B |
| November 05, 2024 | 1.002B |
| November 04, 2024 | 1.094B |
| November 01, 2024 | 1.108B |
| October 31, 2024 | 1.089B |
| October 30, 2024 | 1.098B |
| October 29, 2024 | 1.123B |
| October 28, 2024 | 1.133B |
| October 25, 2024 | 1.125B |
| October 24, 2024 | 1.160B |
| October 23, 2024 | 1.194B |
| October 22, 2024 | 1.215B |
| October 21, 2024 | 1.237B |
| October 18, 2024 | 1.242B |
| Date | Value |
|---|---|
| October 17, 2024 | 1.270B |
| October 16, 2024 | 1.273B |
| October 15, 2024 | 1.207B |
| October 14, 2024 | 1.170B |
| October 11, 2024 | 1.089B |
| October 10, 2024 | 1.044B |
| October 09, 2024 | 1.050B |
| October 08, 2024 | 1.101B |
| October 07, 2024 | 1.070B |
| October 04, 2024 | 1.150B |
| October 03, 2024 | 1.144B |
| October 02, 2024 | 1.144B |
| October 01, 2024 | 1.167B |
| September 30, 2024 | 1.263B |
| September 27, 2024 | 1.159B |
| September 26, 2024 | 1.322B |
| September 25, 2024 | 1.255B |
| September 24, 2024 | 1.212B |
| September 23, 2024 | 1.088B |
| September 20, 2024 | 1.221B |
| September 19, 2024 | 1.249B |
| September 18, 2024 | 1.247B |
| September 17, 2024 | 1.294B |
| September 16, 2024 | 1.152B |
| September 13, 2024 | 1.142B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
4.926M
Minimum
Nov 22 2019
5.135B
Maximum
Jul 28 2021
982.61M
Average
849.40M
Median
Enterprise Value Benchmarks
| Bristol-Myers Squibb Co | 159.82B |
| Seelos Therapeutics Inc | 10.03M |
| EyePoint Pharmaceuticals Inc | 316.10M |
| PTC Therapeutics Inc | 2.580B |
| Adverum Biotechnologies Inc | -33.63M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -27.94M |
| Total Expenses (Quarterly) | 30.62M |
| EPS Diluted (Quarterly) | -0.58 |
| Earnings Yield | -4.29% |
| Operating Earnings Yield | 2.16% |
| Normalized Earnings Yield | 14.79 |